- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech Potentially Undervalued Companies
Australian Pharmaceuticals & Biotech Potentially Undervalued Companies
UPDATED Jul 03, 2022
Companies with a Value score of at least 3, ordered by Value score
33 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| PBPProbiotec | AU$2.21 | -1.8% | 6.8% | AU$181.4m | AU$3.04 | PE21.7x | E25.2% | 2.3% | ||
| AVHAVITA Medical | AU$1.48 | -8.7% | -72.2% | AU$180.0m | AU$3.42 | PS4.7x | E49.1% | n/a | ||
| AVHAVITA Medical | AU$1.46 | -10.0% | -72.5% | AU$180.0m | AU$3.46 | PS4.6x | E49.1% | n/a | ||
| ARXAroa Biosurgery | AU$0.68 | 4.7% | -42.6% | AU$221.1m | AU$1.25 | PS6.4x | E87.7% | n/a | ||
| MYXMayne Pharma Group | AU$0.26 | -1.9% | -20.0% | AU$458.9m | n/a | PS1.2x | E86.4% | 0% | ||
| PBPProbiotec | AU$2.23 | -0.9% | 7.7% | AU$181.4m | AU$3.04 | PE21.9x | E25.2% | 2.2% | ||
| KZAKazia Therapeutics | AU$0.61 | -2.4% | -54.8% | AU$85.3m | AU$1.90 | PS5.6x | E59.5% | n/a | ||
| MYXMayne Pharma Group | AU$0.26 | -2.8% | -21.4% | AU$458.9m | n/a | PS1.2x | E86.4% | 0% | ||
| KZAKazia Therapeutics | AU$0.61 | -0.8% | -55.3% | AU$85.3m | AU$1.90 | PS5.6x | E59.5% | n/a | ||
| TRJTrajan Group Holdings | AU$2.05 | 0.5% | -14.6% | AU$300.4m | AU$3.22 | PS3.7x | E80.9% | n/a | ||
| IMMImmutep | AU$0.30 | -4.8% | -43.4% | AU$264.8m | AU$1.20 | PS70.9x | E62.9% | n/a | ||
| CTECryosite | AU$0.68 | 4.6% | 74.4% | AU$32.2m | n/a | PE28.9x | n/a | 0% | ||
| IMMImmutep | AU$0.32 | 3.2% | -39.6% | AU$264.8m | AU$1.25 | PS73.2x | E62.9% | n/a | ||
| CTECryosite | AU$0.59 | 0% | 43.4% | AU$32.2m | n/a | PE28x | n/a | 0% | ||
| CUVClinuvel Pharmaceuticals | AU$15.25 | -5.5% | -46.6% | AU$751.0m | AU$27.66 | PE31.1x | E29.4% | 0.2% | ||
| CAUCronos Australia | AU$0.26 | 0% | 126.1% | AU$137.7m | n/a | PS6.3x | n/a | n/a | ||
| IDTIDT Australia | AU$0.12 | 9.1% | -63.1% | AU$28.9m | n/a | PE13.2x | n/a | 0% | ||
| CAUCronos Australia | AU$0.24 | 2.1% | 122.7% | AU$137.7m | n/a | PS6.2x | n/a | n/a | ||
| CUVClinuvel Pharmaceuticals | AU$15.93 | -1.2% | -44.2% | AU$751.0m | AU$27.57 | PE32.6x | E29.4% | 0.2% | ||
| MDCMedlab Clinical | AU$0.059 | 34.1% | -64.2% | AU$18.5m | n/a | PS4.5x | S48.7% | n/a | ||
| MSBMesoblast | AU$0.68 | 2.3% | -66.8% | AU$441.9m | AU$1.53 | PS30.1x | E65.1% | n/a | ||
| MVPMedical Developments International | AU$1.64 | 9.0% | -63.9% | AU$114.8m | AU$4.82 | PS5.1x | E53.2% | 0% | ||
| CSLCSL | AU$269.23 | -1.1% | -4.5% | AU$129.7b | AU$319.21 | PE37.9x | E14.8% | 1.2% | ||
| MDCMedlab Clinical | AU$0.054 | 20.0% | -66.3% | AU$18.5m | n/a | PS4.1x | S48.7% | n/a |